<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00902278</url>
  </required_header>
  <id_info>
    <org_study_id>H 13000</org_study_id>
    <nct_id>NCT00902278</nct_id>
  </id_info>
  <brief_title>Immune Responses Induced by Different Licensed Influenza Vaccines</brief_title>
  <official_title>Immune Response Induced by Different Manufacturers of Influenza Vaccines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Massachusetts, Worcester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Massachusetts, Worcester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this research is to find out how the body's immune system responds to different
      manufacturer's &quot;flu&quot; vaccines.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are currently five licensed inactivated influenza vaccines approved for use in the
      United States by the Food and Drug Administration.Current influenza virus vaccines consist of
      3 components: the HA protein from an H1N1 virus, an H3N2 and an influenza B virus.Influenza
      vaccines are evaluated and approved by the FDA on the basis of HA and NA content. However,
      different manufacturing processes are involved in the preparation of these commercial
      vaccines and evidence suggests that each of these vaccines contain similar patterns of HA
      protein but different patterns of influenza influenza internal proteins such as NP and M1.
      The presence of these additional internal proteins of influenza virus which are targets of T
      cell responses suggest not only the potential for additional protection derived from
      influenza vaccines other than antibody mediated protection but also differential levels of T
      cell mediated protection between different manufacturers of commercial influenza
      vaccines.Each subject will have four blood samples taken- prevaccination and at Days 7, 14,30
      and 3-5 months post vaccination. These samples will be tested for T and B cell responses and
      the results compared between different manufacturers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>T Cell Responses Following Immunization</measure>
    <time_frame>Prevaccination and approximately 7 days,14 days ,1month and up to 3-5 months post vaccination</time_frame>
    <description>Comparison of mean peak fold increases in ELISPOT H1N1, H3N2, and B responses between different vaccine groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibody Responses Following Immunization</measure>
    <time_frame>Prevaccination and approximately 1 month post vaccination</time_frame>
    <description>Geometric mean fold rise in antibody titer between day 0 ( baseline) and approximately 1 month post vaccination within each vaccine group</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">193</enrollment>
  <condition>Immune Response</condition>
  <arm_group>
    <arm_group_label>Flulaval</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluvirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluzone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluarix</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Affluria</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Flulaval</intervention_name>
    <description>one 0.5-mL dose via intramuscular injection</description>
    <arm_group_label>Flulaval</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluvirin</intervention_name>
    <description>one 0.5-mL dose via intramuscular injection</description>
    <arm_group_label>Fluvirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluzone</intervention_name>
    <description>one 0.5-mL dose via intramuscular injection</description>
    <arm_group_label>Fluzone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluarix</intervention_name>
    <description>one 0.5-mL dose via intramuscular injection</description>
    <arm_group_label>Fluarix</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Afluria</intervention_name>
    <description>one 0.5-mL dose via intramuscular injection</description>
    <arm_group_label>Affluria</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults (18-50 years of age)

          -  Willing to donate a blood sample multiple times

          -  Willing to sign informed consent and HIPAA

        Exclusion Criteria:

          -  Known systemic hypersensitivity reactions to egg proteins (eggs or egg products), to
             chicken proteins

          -  Known hypersensitivity to neomycin, thimerosol (mercury derivative), neomycin, or
             polymyxin

          -  Previous life threatening reaction to influenza vaccine

          -  Individuals with altered immunocompetence state from medical condition ( HIV, cancer)
             or through immunosuppressive therapy(irradiation,corticosteroids, antimetabolites,
             alkylating agents, cytotoxic agents)

          -  Occurrence of neurological syndrome within six weeks of previous influenza
             immunization

          -  Active neurological disorder characterized by changing neurological disorder

          -  Pregnancy

          -  Acute febrile illness

          -  History of anemia or bleeding disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Dawn T Co, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Massachusetts, Worcester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Massachusetts Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2009</study_first_submitted>
  <study_first_submitted_qc>May 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2009</study_first_posted>
  <results_first_submitted>June 1, 2017</results_first_submitted>
  <results_first_submitted_qc>October 17, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">November 20, 2017</results_first_posted>
  <last_update_submitted>October 17, 2017</last_update_submitted>
  <last_update_submitted_qc>October 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Massachusetts, Worcester</investigator_affiliation>
    <investigator_full_name>Mary Co</investigator_full_name>
    <investigator_title>Study Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>influenzavirus A</keyword>
  <keyword>influenzavirus B</keyword>
  <keyword>human influenza</keyword>
  <keyword>T lymphocytes</keyword>
  <keyword>influenza vaccines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>We recruited healthy adults subjects during the 2008-2009, 2009-2010, 2010-2011, and 2011-2012 influenza seasons in a clinical research setting.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Flulaval</title>
          <description>Flulaval: one 0.5-mL dose via intramuscular injection</description>
        </group>
        <group group_id="P2">
          <title>Fluvirin</title>
          <description>Fluvirin: one 0.5-mL dose via intramuscular injection</description>
        </group>
        <group group_id="P3">
          <title>Fluzone</title>
          <description>Fluzone: one 0.5-mL dose via intramuscular injection</description>
        </group>
        <group group_id="P4">
          <title>Fluarix</title>
          <description>Fluarix: one 0.5-mL dose via intramuscular injection</description>
        </group>
        <group group_id="P5">
          <title>Afluria</title>
          <description>Afluria: one 0.5-mL dose via intramuscular injection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="54"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="49"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Flulaval</title>
          <description>Flulaval: one 0.5-mL dose via intramuscular injection</description>
        </group>
        <group group_id="B2">
          <title>Fluvirin</title>
          <description>Fluvirin: one 0.5-mL dose via intramuscular injection</description>
        </group>
        <group group_id="B3">
          <title>Fluzone</title>
          <description>Fluzone: one 0.5-mL dose via intramuscular injection</description>
        </group>
        <group group_id="B4">
          <title>Fluarix</title>
          <description>Fluarix: one 0.5-mL dose via intramuscular injection</description>
        </group>
        <group group_id="B5">
          <title>Afluria</title>
          <description>Afluria: one 0.5-mL dose via intramuscular injection</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="54"/>
            <count group_id="B2" value="36"/>
            <count group_id="B3" value="54"/>
            <count group_id="B4" value="12"/>
            <count group_id="B5" value="37"/>
            <count group_id="B6" value="193"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="37"/>
                    <measurement group_id="B6" value="193"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="25"/>
                    <measurement group_id="B6" value="141"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="37"/>
                    <measurement group_id="B6" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>T Cell Responses Following Immunization</title>
        <description>Comparison of mean peak fold increases in ELISPOT H1N1, H3N2, and B responses between different vaccine groups</description>
        <time_frame>Prevaccination and approximately 7 days,14 days ,1month and up to 3-5 months post vaccination</time_frame>
        <population>Data was collected only for participants from the 2008-2009 influenza season. Data was not collected for Flulaval group.Only participants with evaluable data were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval</title>
            <description>Flulaval: one 0.5-mL dose via intramuscular injection</description>
          </group>
          <group group_id="O2">
            <title>Fluvirin</title>
            <description>Fluvirin: one 0.5-mL dose via intramuscular injection</description>
          </group>
          <group group_id="O3">
            <title>Fluzone</title>
            <description>Fluzone: one 0.5-mL dose via intramuscular injection</description>
          </group>
          <group group_id="O4">
            <title>Fluarix</title>
            <description>Fluarix: one 0.5-mL dose via intramuscular injection</description>
          </group>
          <group group_id="O5">
            <title>Afluria</title>
            <description>Afluria: one 0.5-mL dose via intramuscular injection</description>
          </group>
        </group_list>
        <measure>
          <title>T Cell Responses Following Immunization</title>
          <description>Comparison of mean peak fold increases in ELISPOT H1N1, H3N2, and B responses between different vaccine groups</description>
          <population>Data was collected only for participants from the 2008-2009 influenza season. Data was not collected for Flulaval group.Only participants with evaluable data were included in the analysis.</population>
          <units>fold change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 virus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1.5" spread=".55"/>
                    <measurement group_id="O3" value="1.7" spread=".84"/>
                    <measurement group_id="O4" value="1.9" spread=".56"/>
                    <measurement group_id="O5" value="1.6" spread=".71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 virus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="2.4" spread="1.28"/>
                    <measurement group_id="O3" value="2.1" spread="1.34"/>
                    <measurement group_id="O4" value="2.7" spread="1.23"/>
                    <measurement group_id="O5" value="1.7" spread=".60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B virus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1.5" spread=".61"/>
                    <measurement group_id="O3" value="1.6" spread=".59"/>
                    <measurement group_id="O4" value="1.6" spread=".59"/>
                    <measurement group_id="O5" value="1.4" spread=".61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Responses Following Immunization</title>
        <description>Geometric mean fold rise in antibody titer between day 0 ( baseline) and approximately 1 month post vaccination within each vaccine group</description>
        <time_frame>Prevaccination and approximately 1 month post vaccination</time_frame>
        <population>Data was collected only for participants from the 2008-2009 influenza season. Data was not collected for the flulaval group. Only participants with evaluable data were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval</title>
            <description>Flulaval: one 0.5-mL dose via intramuscular injection</description>
          </group>
          <group group_id="O2">
            <title>Fluvirin</title>
            <description>Fluvirin: one 0.5-mL dose via intramuscular injection</description>
          </group>
          <group group_id="O3">
            <title>Fluzone</title>
            <description>Fluzone: one 0.5-mL dose via intramuscular injection</description>
          </group>
          <group group_id="O4">
            <title>Fluarix</title>
            <description>Fluarix: one 0.5-mL dose via intramuscular injection</description>
          </group>
          <group group_id="O5">
            <title>Afluria</title>
            <description>Afluria: one 0.5-mL dose via intramuscular injection</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Responses Following Immunization</title>
          <description>Geometric mean fold rise in antibody titer between day 0 ( baseline) and approximately 1 month post vaccination within each vaccine group</description>
          <population>Data was collected only for participants from the 2008-2009 influenza season. Data was not collected for the flulaval group. Only participants with evaluable data were included in this analysis.</population>
          <units>fold change</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="7.32" lower_limit="-61.28" upper_limit="75.92"/>
                    <measurement group_id="O3" value="7.02" lower_limit="-54.6" upper_limit="68.62"/>
                    <measurement group_id="O4" value="5.71" lower_limit="-9.49" upper_limit="20.91"/>
                    <measurement group_id="O5" value="5.26" lower_limit="-5.88" upper_limit="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="7.6" lower_limit="-30.1" upper_limit="45.3"/>
                    <measurement group_id="O3" value="7.2" lower_limit="-74.8" upper_limit="89.2"/>
                    <measurement group_id="O4" value="4.9" lower_limit="-6.2" upper_limit="16"/>
                    <measurement group_id="O5" value="5.6" lower_limit="-14.9" upper_limit="26.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="3.4" lower_limit="-41.6" upper_limit="48.4"/>
                    <measurement group_id="O3" value="9.3" lower_limit="-34" upper_limit="52.6"/>
                    <measurement group_id="O4" value="9.6" lower_limit="-52.99" upper_limit="72.21"/>
                    <measurement group_id="O5" value="4.0" lower_limit="-6.9" upper_limit="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Only participants with available data were included in the analysis.</desc>
      <group_list>
        <group group_id="E1">
          <title>Flulaval</title>
          <description>Flulaval: one 0.5-mL dose via intramuscular injection</description>
        </group>
        <group group_id="E2">
          <title>Fluvirin</title>
          <description>Fluvirin: one 0.5-mL dose via intramuscular injection</description>
        </group>
        <group group_id="E3">
          <title>Fluzone</title>
          <description>Fluzone: one 0.5-mL dose via intramuscular injection</description>
        </group>
        <group group_id="E4">
          <title>Fluarix</title>
          <description>Fluarix: one 0.5-mL dose via intramuscular injection</description>
        </group>
        <group group_id="E5">
          <title>Afluria</title>
          <description>Afluria: one 0.5-mL dose via intramuscular injection</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="53"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="11"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sore throat</sub_title>
                <description>Scratchy or sore throat</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <description>abdominal pain or cramps</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>fevers</sub_title>
                <description>fevers, feverish,</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>sweats</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arm soreness</sub_title>
                <description>Soreness or tenderness</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="53"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Joint pain</sub_title>
                <description>Includes neck, back, shoulder pain</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Muscle stiffness/achiness/pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="52"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="53"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Runny nose</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Sniffles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>&quot; Cold symptoms&quot;</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site soreness/tenderness</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="52"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="34"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="53"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E5" events="13" subjects_affected="13" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>injection site swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mary Co</name_or_title>
      <organization>University of Massachusetts Medical School</organization>
      <phone>5088562927</phone>
      <email>mary.co@umassmed.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

